Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib

Seungtaek Lim, Jungwoo Han, Gun Min Kim, KwangHyub Han, Hye Jin Choi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background and Aim: Sorafenib is now considered as a standard treatment for advanced hepatocellular carcinoma (HCC). We evaluated the effect of hepatitis B virus (HBV) DNA titers on prognosis in HCC patients treated with sorafenib. Methods: From 2008 to 2012, 78 HBV-related HCC patients who received sorafenib treatment at Severance Hospital were included in our analysis. The effect of pretreatment HBV-DNA levels on clinical outcomes for use in predicting prognosis after treatment with sorafenib was examined by univariate and multivariate analysis. Results: Median overall survival and median progression-free survival were 5.2 months (95% confidence interval: 4.0-6.4) and 3.5 months (95% confidence interval: 2.3-4.7), respectively. Multivariate analysis revealed high levels of HBV-DNA (>2000IU/mL) to be an independent risk factor for worse overall survival (P=0.005; hazard ratio, 2.85) and disease progression among patients who did not receive concomitant prophylactic antiviral therapy during sorafenib treatment (P=0.008; hazard ratio, 87.4). Moreover, viral reactivation occurred more frequently in patients who did not receive concomitant prophylactic antiviral therapy than in those who did (4/38 vs 0/40; P=0.025). Conclusion: Higher HBV-DNA levels prior to sorafenib treatment were associated with poorer prognosis and increased viral reactivation thereafter. These results suggest the potential usefulness of prophylactic antiviral therapy when treating HBV-related HCC patients with sorafenib.

Original languageEnglish
Pages (from-to)1024-1031
Number of pages8
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume30
Issue number6
DOIs
Publication statusPublished - 2015 Jun 1

Fingerprint

Viral Load
Hepatitis B
Hepatocellular Carcinoma
Hepatitis B virus
Survival
Antiviral Agents
DNA
Therapeutics
Multivariate Analysis
Confidence Intervals
sorafenib
Disease-Free Survival
Disease Progression

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{2d660e52a7bc4d61bef941a03dc2aa1a,
title = "Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib",
abstract = "Background and Aim: Sorafenib is now considered as a standard treatment for advanced hepatocellular carcinoma (HCC). We evaluated the effect of hepatitis B virus (HBV) DNA titers on prognosis in HCC patients treated with sorafenib. Methods: From 2008 to 2012, 78 HBV-related HCC patients who received sorafenib treatment at Severance Hospital were included in our analysis. The effect of pretreatment HBV-DNA levels on clinical outcomes for use in predicting prognosis after treatment with sorafenib was examined by univariate and multivariate analysis. Results: Median overall survival and median progression-free survival were 5.2 months (95{\%} confidence interval: 4.0-6.4) and 3.5 months (95{\%} confidence interval: 2.3-4.7), respectively. Multivariate analysis revealed high levels of HBV-DNA (>2000IU/mL) to be an independent risk factor for worse overall survival (P=0.005; hazard ratio, 2.85) and disease progression among patients who did not receive concomitant prophylactic antiviral therapy during sorafenib treatment (P=0.008; hazard ratio, 87.4). Moreover, viral reactivation occurred more frequently in patients who did not receive concomitant prophylactic antiviral therapy than in those who did (4/38 vs 0/40; P=0.025). Conclusion: Higher HBV-DNA levels prior to sorafenib treatment were associated with poorer prognosis and increased viral reactivation thereafter. These results suggest the potential usefulness of prophylactic antiviral therapy when treating HBV-related HCC patients with sorafenib.",
author = "Seungtaek Lim and Jungwoo Han and Kim, {Gun Min} and KwangHyub Han and Choi, {Hye Jin}",
year = "2015",
month = "6",
day = "1",
doi = "10.1111/jgh.12898",
language = "English",
volume = "30",
pages = "1024--1031",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "6",

}

Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. / Lim, Seungtaek; Han, Jungwoo; Kim, Gun Min; Han, KwangHyub; Choi, Hye Jin.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 30, No. 6, 01.06.2015, p. 1024-1031.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib

AU - Lim, Seungtaek

AU - Han, Jungwoo

AU - Kim, Gun Min

AU - Han, KwangHyub

AU - Choi, Hye Jin

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Background and Aim: Sorafenib is now considered as a standard treatment for advanced hepatocellular carcinoma (HCC). We evaluated the effect of hepatitis B virus (HBV) DNA titers on prognosis in HCC patients treated with sorafenib. Methods: From 2008 to 2012, 78 HBV-related HCC patients who received sorafenib treatment at Severance Hospital were included in our analysis. The effect of pretreatment HBV-DNA levels on clinical outcomes for use in predicting prognosis after treatment with sorafenib was examined by univariate and multivariate analysis. Results: Median overall survival and median progression-free survival were 5.2 months (95% confidence interval: 4.0-6.4) and 3.5 months (95% confidence interval: 2.3-4.7), respectively. Multivariate analysis revealed high levels of HBV-DNA (>2000IU/mL) to be an independent risk factor for worse overall survival (P=0.005; hazard ratio, 2.85) and disease progression among patients who did not receive concomitant prophylactic antiviral therapy during sorafenib treatment (P=0.008; hazard ratio, 87.4). Moreover, viral reactivation occurred more frequently in patients who did not receive concomitant prophylactic antiviral therapy than in those who did (4/38 vs 0/40; P=0.025). Conclusion: Higher HBV-DNA levels prior to sorafenib treatment were associated with poorer prognosis and increased viral reactivation thereafter. These results suggest the potential usefulness of prophylactic antiviral therapy when treating HBV-related HCC patients with sorafenib.

AB - Background and Aim: Sorafenib is now considered as a standard treatment for advanced hepatocellular carcinoma (HCC). We evaluated the effect of hepatitis B virus (HBV) DNA titers on prognosis in HCC patients treated with sorafenib. Methods: From 2008 to 2012, 78 HBV-related HCC patients who received sorafenib treatment at Severance Hospital were included in our analysis. The effect of pretreatment HBV-DNA levels on clinical outcomes for use in predicting prognosis after treatment with sorafenib was examined by univariate and multivariate analysis. Results: Median overall survival and median progression-free survival were 5.2 months (95% confidence interval: 4.0-6.4) and 3.5 months (95% confidence interval: 2.3-4.7), respectively. Multivariate analysis revealed high levels of HBV-DNA (>2000IU/mL) to be an independent risk factor for worse overall survival (P=0.005; hazard ratio, 2.85) and disease progression among patients who did not receive concomitant prophylactic antiviral therapy during sorafenib treatment (P=0.008; hazard ratio, 87.4). Moreover, viral reactivation occurred more frequently in patients who did not receive concomitant prophylactic antiviral therapy than in those who did (4/38 vs 0/40; P=0.025). Conclusion: Higher HBV-DNA levels prior to sorafenib treatment were associated with poorer prognosis and increased viral reactivation thereafter. These results suggest the potential usefulness of prophylactic antiviral therapy when treating HBV-related HCC patients with sorafenib.

UR - http://www.scopus.com/inward/record.url?scp=84928330642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928330642&partnerID=8YFLogxK

U2 - 10.1111/jgh.12898

DO - 10.1111/jgh.12898

M3 - Article

VL - 30

SP - 1024

EP - 1031

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 6

ER -